Discover our Portfolio


Pharnext, a biopharmaceutical company created in 2007, is developing new treatments targeting severe neurodegenerative diseases – rare or common – current without satisfactory therapeutic solutions.

Pharnext has developed a new drug paradigm called PLEOTHERAPY ™. The approach is based on a proprietary technological platform that relies on the pharmacology of biological networks. The company identifies and develops synergistic combinations of drugs already approved but for other diseases. These treatments, called PLEODRUG ™, are developed at new, lower optimal doses and under a new galenic formulation. The advantages of PLEODRUG ™ are important: excellent safety profile, simultaneous action on several therapeutic targets, strong and robust intellectual property.



Contact Truffle Capital

10 + 2 =

[sg_popup id=2]
5 Rue de la Baume, 75008 Paris, France Tel: +33 1 82 28 46 00



Truffle Capital

Truffle Capital

5 Rue de la Baume 75008 Paris France
Tel: +33 1 82 28 46 00

© 2018 Truffle Capital

Truffle Capital 2018

Social Networks